RNA

UT Health San Antonio secures $16.4 million from CPRIT over six months, adding transformative expertise, bolstering cancer research

Retrieved on: 
Friday, March 8, 2024

SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) (https://uthscsa.edu/) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas (https://www.cprit.state.tx.us/about-us) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.

Key Points: 
  • SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) ( https://uthscsa.edu/ ) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas ( https://www.cprit.state.tx.us/about-us ) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.
  • The Mays Cancer Center at UT Health San Antonio ( https://cancer.uthscsa.edu/ ) is one of only four National Cancer Institute-designated Cancer Centers in Texas.
  • The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas.
  • The Greehey Children's Cancer Research Institute ( https://cancer.uthscsa.edu/gccri ) is one of only two institutes in the United States dedicated solely to pediatric cancer research.

Synthetic DNA Sheds Light on Mysterious Difference Between Living Cells at Different Points in Evolution

Retrieved on: 
Wednesday, March 6, 2024

Is it just noise, a side effect of evolution, or does it have functions?

Key Points: 
  • Is it just noise, a side effect of evolution, or does it have functions?
  • A research team at NYU Langone Health sought to answer the question by creating a large, synthetic gene, with its DNA code in reverse order from its natural parent.
  • Then they put synthetic gene into yeast and mouse stem cells and watched transcription levels in each.
  • The study authors use yeast cells to assemble long DNA sequences in a single step, and then deliver the them into mouse embryonic stem cells.

Why some RNA drugs work better than others

Retrieved on: 
Wednesday, March 6, 2024

CSHL Associate Professor Justin Kinney, Krainer, and postdoc Yuma Ishigami have figured out why some splicing-based drugs tend to work better than others.

Key Points: 
  • CSHL Associate Professor Justin Kinney, Krainer, and postdoc Yuma Ishigami have figured out why some splicing-based drugs tend to work better than others.
  • To better understand how this drug works, the Kinney and Krainer labs analyzed risdiplam's interactions with RNA.
  • "Our new study provides insights into the action and specificity of splice-modifying drugs," Krainer says.
  • "This should facilitate the development of more effective drugs and drug combinations for a variety of diseases."

Latest Updates of Viva Biotech's Portfolio Companies

Retrieved on: 
Wednesday, March 6, 2024

NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs). Recently they announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy. AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease.

Key Points: 
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva Biotech's portfolio companies have new updates.
  • NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs).
  • Previously, the company had completed a $5.4 million seed funding round, with investors including Rev1 Ventures, Broadview Ventures, and Viva Biotech.

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024

Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.

Key Points: 
  • Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.
  • "We are excited to present our latest preclinical data at the AACR Annual Meeting, showcasing our significant progress in advancing novel small molecule therapies for oncology.
  • This year, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, the lead program within Ryvu's synthetic lethality pipeline.
  • Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable drug-like properties and effective PRMT5 inhibition dependent on MTA binding.

Datasea Expects Approximately 1,128% Revenue Growth in 2024

Retrieved on: 
Tuesday, March 5, 2024

BEIJING, March 5, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a Nevada corporation engaged in innovative business segments for Acoustics Intelligence and 5G-AI multimodal communication technology in China and the US, issued guidance today for expecting a revenue of approximately $86.0 million for the Company's full year ended June 30, 2024.

Key Points: 
  • BEIJING, March 5, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a Nevada corporation engaged in innovative business segments for Acoustics Intelligence and 5G-AI multimodal communication technology in China and the US, issued guidance today for expecting a revenue of approximately $86.0 million for the Company's full year ended June 30, 2024.
  • This represents approximately a 1,128% increase from revenue of $7.0 million which was reported for fiscal year ended June 30, 2023.
  • Datasea's CEO Zhixin Liu commented, "Our guidance of approximately $86.0 million in revenue is due to projected strong results from both of our business segments.
  • Our operating model encompasses distinct customer bases and sources of revenue which we believe will create long-term value for our shareholders."

Zymo Research Pioneers a Breakthrough in Large-scale Animal-free RNase A Production

Retrieved on: 
Tuesday, March 5, 2024

This breakthrough will enable the widespread use of recombinant RNase A in applications where an animal-free enzyme is preferred.

Key Points: 
  • This breakthrough will enable the widespread use of recombinant RNase A in applications where an animal-free enzyme is preferred.
  • Recognizing these challenges, Zymo Research has developed PureRec RNase A, an animal-free recombinant RNase A.
  • PureRec RNase A was developed and manufactured in Zymo Research's state-of-the-art facility in California, empowered by specialized expertise and advanced fermentation and bioprocessing technologies.
  • For more information or bulk inquiries on Zymo Research's recombinant RNase A, please check out PureRec RNase A .

Zymo Research Pioneers a Breakthrough in Large-scale Animal-free RNase A Production

Retrieved on: 
Tuesday, March 5, 2024

This breakthrough will enable the widespread use of recombinant RNase A in applications where an animal-free enzyme is preferred.

Key Points: 
  • This breakthrough will enable the widespread use of recombinant RNase A in applications where an animal-free enzyme is preferred.
  • RNase A is a critical enzyme extensively utilized in plasmid and genomic DNA purification processes due to its efficacy in degrading RNA contaminants.
  • Recognizing these challenges, Zymo Research has developed PureRec RNase A, an animal-free recombinant RNase A.
  • For more information or bulk inquiries on Zymo Research's recombinant RNase A, please check out PureRec RNase A .

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on March 7, 2024

Retrieved on: 
Tuesday, March 5, 2024

SAN DIEGO, March 5, 2024 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on March 7, 2024 (https://emerginggrowth.com/conference/).

Key Points: 
  • Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
  • SAN DIEGO, March 5, 2024 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on March 7, 2024 ( https://emerginggrowth.com/conference/ ).
  • Regen BioPharma, Inc. will be presenting at 3:10-3:20 Eastern time on Wednesday March 7, 2024.
  • Please register here to ensure you are able to attend the conference and receive any updates that are released https://goto.webcasts.com/starthere.jsp?ei=1650531&tp_key=ca9510e531&sti... .

Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting

Retrieved on: 
Tuesday, March 5, 2024

SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC: NVTA), a leading medical genetics company, are showcasing their work next week at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada from March 12-16. The meeting's clinical agenda will include presentations on both research and clinical topics that promote the science and practice of clinical genetics and genomics.

Key Points: 
  • SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC: NVTA), a leading medical genetics company, are showcasing their work next week at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada from March 12-16.
  • The meeting's clinical agenda will include presentations on both research and clinical topics that promote the science and practice of clinical genetics and genomics.
  • "The ACMG Annual Clinical Genetics Meeting is an incredible opportunity for our researchers and collaborators to highlight ongoing scientific advancements to support genetics-informed patient care," said W. Michael Korn, M.D., chief medical officer at Invitae.
  • Invitae plans to present posters (P164 and P073) about Lynch syndrome and VUS in mismatch repair (MMR) genes and multiplex assays of variant effects (MAVEs).